Please login to the form below

Not currently logged in
Email:
Password:

liver transplant

This page shows the latest liver transplant news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Boehringer bolsters NASH pipeline with $870m Yuhan deal

target for NASH and other liver diseases.  Around $40m of the total is in upfront or near-term payments. ... NASH is characterised by a build-up of fat that can lead to fibrosis, cirrhosis and - in some patients - the need for a liver transplant.

Latest news

  • Promethera’s liver failure stem cell therapy clears first hurdle Promethera’s liver failure stem cell therapy clears first hurdle

    Technique could be alternative to transplant. A stem cell-based therapy for a serious form of liver failure has been shown to be safe and improve liver function biomarkers in a ... At the moment, the only treatment for patients whose liver disease has

  • Genfit launches $135m IPO to back NASH plans Genfit launches $135m IPO to back NASH plans

    fund a phase 4 post-marketing study in patients with the liver disease. ... It causes fatty build-up and fibrosis in the liver, in serious cases leading to cirrhosis and the need for a liver transplant.

  • Liver specialist Genfit files $120m IPO on Nasdaq Liver specialist Genfit files $120m IPO on Nasdaq

    Funds will go towards NASH candidate, a companion diagnostic and a liver disease drug. ... for a liver transplant.

  • Intercept NASH drug closes in on FDA approval Intercept NASH drug closes in on FDA approval

    NASH causes fatty build-up and fibrosis in the liver, which in serious cases can lead to cirrhosis and the need for a liver transplant. ... Intercept’s trial enrolled mainly patients with stage 2 and 3 liver fibrosis, with a small group of patient with

  • Gilead lead NASH drug flunks phase 3 test Gilead lead NASH drug flunks phase 3 test

    It causes fatty build-up and fibrosis in the liver, in serious cases leading to cirrhosis and the need for a liver transplant. ... In phase 2 testing, VK2809 was shown to significantly reduce fat in the liver – another key pathology in NASH – and

More from news
Approximately 3 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    NASH and biosimilars. One therapeutic indication that could be seen to be gaining much attention was NASH, which is the fastest growing cause of liver cancer and liver transplant in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics